Pharmacological correction of immunometabolic disorders in patients with endometrioma along with chronic inflammatory diseases of the genital tract

The objective: to determine the markers of inflammatory process, development and implementation methods for pharmacological correction immunometabolic disorders in patients with endometrioma on background chronic processes pelvic organs. Materials methods. A complex clinical laboratory examination 90 ovarian inflammation was carried out. Of these patients, comparison group included 45 who received basic therapy (antibacterial drugs cefotaxime metronidazole, vitamin (B vitamins), combined oral contraceptives dienogest). Patients main (45 women) anti-inflammatory antibiotic therapy, together that improve microcirculation have systemic local thrombolytic properties (tissue antihypoxant, deproteinized hemoderivative drug from calf blood two-component suppositories) dienogest D3. control 30 gynecologically healthy women.ELISA-method used tumor necrosis factor-α (TNF-α) level, interleukins (IL) 1β, 4, 10, interferon-γ serum cervical mucus, immunoglobulins A, M, G serum, C-reactive protein (CRP), neopterin 25-hydroxyvitamin-D3. Results. We determined disease at levels there are an increased level proinflammatory cytokines decreased cytokines, as well IFN-γ CRP – 8.2 times, 2.7 times (p <0.05) relative women. use proposed treatment program leads normalize IgG cytokine indices within a month. significantly reduced group, both mucus. There decrease by 1.8 after treatment.Conclusions. Additional criteria diagnosis process significant increase pro-inflammatory (TNF-α, IL-1β) (IL-4, IL-10) neopterin.Studies suggest has corrective effect altered parameters metabolic immune status, which explains importance this antibacterial immunomodulatory, antiviral drugs.